Who is sponsoring NCT03653715?

NCT03653715 is sponsored by Clerio Vision, Inc..

What drugs are being tested in NCT03653715?

Interventions in NCT03653715: Clerio Vision LIRIC-modified Bifocal Contact Lens, Johnson & Johnson 1-Day Acuvue Moist Multifocal Contact Lens, Johnson & Johnson 1-Day Acuvue Moist Contact Lens, Clerio Vision Single Vision Contact Lens.

What condition does NCT03653715 study?

NCT03653715 studies Presbyopia.

Is NCT03653715 still recruiting?

NCT03653715 is currently completed. Last updated 19 April 2019.

Last reviewed 2019-04-19 · How we verify

NCT03653715

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Bifocal Contact Lens Study for Adults With Age-Related Near Vision Loss

Completed NA Last updated 19 April 2019

What this trial tests

NA trial testing Clerio Vision LIRIC-modified Bifocal Contact Lens in Presbyopia in 30 participants. Completed in 12 October 2018.

Timeline

6 August 2018

Primary endpoint
27 August 2018

12 October 2018

Quick facts

Lead sponsor	Clerio Vision, Inc.
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	double
Primary purpose	treatment
Enrollment	30
Start date	6 August 2018
Primary completion	27 August 2018
Estimated completion	12 October 2018
Sites	1 location across United States

Drugs / interventions tested

Clerio Vision LIRIC-modified Bifocal Contact Lens
Johnson & Johnson 1-Day Acuvue Moist Multifocal Contact Lens
Johnson & Johnson 1-Day Acuvue Moist Contact Lens
Clerio Vision Single Vision Contact Lens

Conditions studied

Presbyopia — all drugs for Presbyopia →

Sponsor

Clerio Vision, Inc.

Who can join

21 and older, any sex, with Presbyopia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary objective of this study is to evaluate the distance, intermediate and near visual performance of Clerio designed single vision and Clerio designed LIRIC modified bifocal lenses (+2.00D add) compared to commercially available single vision and multifocal lenses.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Presbyopia

Currently open trials in the same condition.

NCT07444658 — Performance of Two Daily Disposable Multifocal Contact Lenses · NA · recruiting
NCT07284966 — Comfort and Vision With TOTAL30 Multifocal Lenses · recruiting
NCT07077967 — Luminous Efficiency Function V(λ)' of Patients That Underwent Pseudophakic Presbyopic Corrections With EDOF IOLs · recruiting
NCT07113210 — Quality of Life in Presbyopic Patients Who Are Treated With Qlosi · Phase 4 · recruiting
NCT06948357 — Efficacy and Safety of BRIMOCHOL PF and CARBACHOL PF in Chinese Presbyopia Patients · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03653715 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Clerio Vision, Inc.
Last refreshed: 19 April 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03653715.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing